Online citations, reference lists, and bibliographies.
← Back to Search

Transient Elastography For The Diagnosis Of Liver Fibrosis: A Systematic Review Of Economic Evaluations

S. Katwyk, D. Coyle, C. Cooper, K. Pussegoda, Chris Cameron, B. Skidmore, S. Brener, D. Moher, K. Thavorn
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Liver biopsy remains the gold standard for the diagnosis of liver fibrosis, but its use as a diagnostic tool is limited by its invasive nature and high cost.
This paper references
Biomedical research: increasing value, reducing waste
Published Online (2014)
10.1111/jvh.12469
Cost‐effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation
C. Crossan (2016)
10.1111/j.1478-3231.2012.02781.x
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography
R. Myers (2012)
10.3310/hta19090
Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
C. Crossan (2015)
10.1111/j.1440-1746.2009.05778.x
An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis
J. Carlson (2009)
10.1007/978-94-017-7411-6_6
Ultrasound Elastography in the Assessment of Liver Fibrosis
Q. Lu (2016)
10.1136/gut.2003.020263
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications
L. Benvegnù (2004)
10.1136/gut.2005.084475
An appraisal of the histopathological assessment of liver fibrosis
R. A. Standish (2006)
Methods for the economic evaluation of health care programmes, 3rd ed
G. Adamiak (2006)
10.1258/135581907779497567
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence
A. Culyer (2007)
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
A. Laupacis (1992)
10.1155/2014/675409
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
G. Sebastiani (2014)
Health Technology Assessment of Transient Elastography in Liver Disease
R Steadman (2012)
10.1111/J.1524-4733.2005.00045.X
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
S. Ramsey (2005)
10.1136/jech.41.4.355-a
Methods for the economic evaluation of health care programmes
S. Wilson (1987)
10.1016/J.ULTRASMEDBIO.2003.07.001
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.
L. Sandrin (2003)
10.1177/0272989X0002000310
Willingness to Pay for a Quality-adjusted Life Year
R. Hirth (2000)
Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration
J. Higgins (2013)
Liver Disease in Canada: a Crisis in the Making
(2013)
10.1007/s10620-013-2705-y
Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK
C. Canavan (2013)
10.1016/J.JHEP.2005.10.013
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
G. D'Amico (2006)
10.1002/hep.27296
Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
E. Tsochatzis (2014)
10.1111/j.1572-0241.2002.06038.x
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
A. Regev (2002)
Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
Jp Higgins (2011)
Health Technology Assessment of Transient Elastography in Liver Disease. Calgary, AB: University of Calgary Health Technology Assessment Unit
R Steadman (2012)
10.3310/hta16040
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
M. Stevenson (2012)
10.1016/j.jval.2013.02.002
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
D. Husereau (2013)
PPPs and exchange rates
OECD. StatExtracts (2016)
10.1053/j.gastro.2010.06.015
Reduced mortality rates following elective percutaneous liver biopsies.
J. West (2010)
Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis.
J. Murtagh (2006)
10.1155/2013/684982
A health technology assessment of transient elastography in adult liver disease.
R. Steadman (2013)



This paper is referenced by
10.1007/s11695-020-05002-4
The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature
Max M. Puthenpura (2020)
10.15537/SMJ.2019.6.23980
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Khalid Alswat (2019)
10.3348/kjr.2019.0109
Validation of a New Point Shear-Wave Elastography Method for Noninvasive Assessment of Liver Fibrosis: A Prospective Multicenter Study
I. Joo (2019)
10.4254/wjh.v9.i17.791
Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
Stephanie Wong (2017)
10.1080/17474124.2019.1653757
Red cell distribution width to platelet ratio for liver fibrosis: a systematic review and meta-analysis of diagnostic accuracy
Gerasimos P. Milas (2019)
10.3969/j.issn.2095-4344.0319
Finite element analysis of shear wave velocity influenced by force in muscle
Qian‐yi Ji (2018)
Evaluation and Staging of Liver Fibrosis-Core Concepts
(2019)
10.1097/MD.0000000000018038
Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in Chinese patients with chronic hepatitis B
W. Yue (2019)
10.1186/s12874-018-0515-9
Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses
Rodolfo Castro (2018)
10.1007/978-3-319-98890-0_1
Clinical Aspects of Alcoholic Liver Disease
Mads Israelsen (2019)
10.1016/j.redox.2018.01.009
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
A. Borrelli (2018)
10.1590/MEDICC.2018.20010009
Liver Stiffness Reference Values for Healthy Cuban Adults
Ángela Elvírez-Gutiérrez (2018)
10.1186/s12876-017-0676-8
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil
H. Perazzo (2017)
10.1007/978-3-319-98890-0
The Human Gut-Liver-Axis in Health and Disease
Aleksander Krag (2019)
10.1111/jgh.14707
Effectiveness of direct‐acting agents for hepatitis C and liver stiffness changing after sustained virological response
F. Fernandes (2019)
10.4103/jfmpc.jfmpc_828_19
Ultrasound shear wave elastography and liver biopsy to determine liver fibrosis in adult patients
Mohammad Momen Gharibvand (2020)
10.5772/INTECHOPEN.84351
Noninvasive Biomarkers for the Diagnosis of Liver Fibrosis and Cirrhosis
D. Rosique-Oramas (2019)
10.1016/j.metabol.2017.03.013
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
M. Doulberis (2017)
Semantic Scholar Logo Some data provided by SemanticScholar